GalocitabineAlternative Names: Neofrutulon; RO 091390
Latest Information Update: 07 Mar 2007
At a glance
- Originator Roche
- Class Antineoplastics; Small molecules
- Mechanism of Action Thymidylate synthase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 07 Mar 2007 Discontinued - Phase-III for Cancer in Japan (unspecified route)
- 09 Nov 2000 No-Development-Reported - Phase-III for Cancer in Japan (Unknown route)